Citigroup Maintains Buy on Zenas BioPharma, Lowers Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 61.6%

Neg 61.6% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and lowers the price target from $43 to $41.